Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Interferon plus ribavirin (IFN/Rib) therapy is currently standard treatment for chronic hepatitis C. Hemolytic anemia, however, is a serious side effect of this treatment, requiring reductions in or complete withdrawal of ribavirin.
We retrospectively investigated the effect of the Kampo medicine Juzen-taiho-to (TJ-48), which contains bone marrow-stimulating compounds, on anemia in 67 patients with chronic hepatitis C, who received IFN/Rib therapy.
The reduction in hemoglobin levels was significantly ameliorated in TJ-48-treated patients (P < 0.05). Consequently, only 13% (4/32) of TJ-48-treated patients received altered doses of ribavirin, while the ribavirin dose had to be reduced or withdrawn in 43% (15/35) of patients in the absence of TJ-48 administration (P < 0.001).
These results indicate the possibility that oral administration of TJ-48 supports IFN/Rib therapy without necessitating ribavirin reduction or withdrawal.
- Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C
Journal of Gastroenterology
Volume 39, Issue 12 , pp 1202-1204
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- chronic hepatitis C
- Industry Sectors
- Author Affiliations
- A1. Jiaikai Imamura Bun-in Hospital, Kagoshima, Japan
- A2. Hayato Medical Center, Kagoshima, Japan
- A3. Jiaikai Imamura Hospital, Kagoshima, Japan
- A4. Yamaguchi Urban Clinic, Kagoshima, Japan
- A5. Kagaoshima Kouseiren Hospital, Kagoshima, Japan
- A6. Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Kyoto, Japan
- A7. Department of Internal Medicine II, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1962, Japan